Abstract Details

Title Identifying Risk Factors for Falls in Parkinson's Disease Using the UPDRS

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 174

Objective

Background BACKGROUND: Falls are a common and serious complication of PD. PD patients are more often admitted to the hospital because of falls than for management of their PD. This underscores the importance of identifying risk for falls in this population.

Design/Methods DESIGN/METHODS: 205 patients reported balance difficulty using a validated, self-administered question, the Barrow Neurological Institute (BNI) balance question. All patients were evaluated using the motor portion of the revised UPDRS including the subtests of gait, freezing of gait (FoG), and postural stability (PS). The t-test was used for comparing continuous variables and a chi- square test was used for comparing categorical variables.

Results RESULTS: Of 205 patients with balance difficulty, 153 patients reported balance difficulty without falls and 52 reported balance difficulty with falls. The patients who fell (fallers) were significantly older, had PD longer, and were more disabled on the UPDRS total motor score and the UPDRS axial score (sum of the scores for arising from a chair, body bradykinesia, posture, gait, FoG, and PS). Fallers had worse FoG, gait, and PS scores. The sensitivity and selectivity of different subtests in predicting falls are: UPDRS gait scores > 2: Sensitivity 75% & specificity 80%; PS scores > 2: 95.8% & 40%; FoG scores > 2: 16.7% (reflecting the small number of FoG patients) & 97.8%.

Conclusions CONCLUSIONS: Balance difficulty is an important symptom in PD. There are differences in disease severity between patients who have balance difficulty with and without falls. The PS subtest has a high sensitivity and low specificity of predicting falls.

Authors/Disclosures
Abraham N. Lieberman, MD, FAAN PRESENTER	No disclosure on file
Narayanan Krishnamurthi	No disclosure on file
Rohit Dhall, MD, FAAN (University of Arkansas for Medical Sciences)	Dr. Dhall has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Best Doctors Inc. Dr. Dhall has stock in Verve Therapeutics Inc. Dr. Dhall has stock in Roche Holding Limited. Dr. Dhall has stock in Enliven Therapeutics Inc. The institution of Dr. Dhall has received research support from Amneal. The institution of Dr. Dhall has received research support from Neuroderm. The institution of Dr. Dhall has received research support from Cerevel Therapeutics. The institution of Dr. Dhall has received research support from Neurocrine. The institution of Dr. Dhall has received research support from Neuraly. The institution of Dr. Dhall has received research support from SPARC. The institution of Dr. Dhall has received research support from Pharma2B. The institution of Dr. Dhall has received research support from Alexion. The institution of Dr. Dhall has received research support from Parkinsons Foundation. The institution of Dr. Dhall has received research support from UCB Pharma. The institution of Dr. Dhall has received research support from Inhibikase Therapeutics. The institution of Dr. Dhall has received research support from Amylyx Pharma.
Sara S. Dhanani, MD (Banner Sun Health Research Institute)	Dr. Dhanani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
	No disclosure on file
Patricia K. Coyle, MD, FAAN (SUNY At Stony Brook)	Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Coyle has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi Genzyme. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GlaxoSmithKline. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. The institution of Dr. Coyle has received research support from CorEvitas LLC. The institution of Dr. Coyle has received research support from Genentech/Roche. The institution of Dr. Coyle has received research support from NINDS. The institution of Dr. Coyle has received research support from Sanofi Genzyme. The institution of Dr. Coyle has received research support from Cleveland Clinic.

��ɫ��

��ɫ��